CA
NZ
UK
AU
IND
US
…
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Ironwood Pharmaceuticals is a commercial-stage biopharma focused on gastrointestinal therapies, with a marketed treatment for chronic idiopathic constipation and IBS-C that generates commercial and royalty revenue.
Long-term growth may be supported by demand for the approved product, potential expansion into new indications or markets, and progress in development-stage programs that could diversify revenue.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 252.42M | 200.66M | 108.86M | 58.94M | -282.37M |
| Net income | 175.06M | 528.45M | 106.18M | -15.31M | -282.37M |
| Selling general administrative | 115.99M | 111.13M | 140.00M | 172.45M | 241.29M |
| Gross profit | 410.60M | 413.75M | 386.39M | 404.54M | 313.89M |
| Reconciled depreciation | 1.42M | 1.52M | 3.56M | 5.58M | 14.22M |
| Ebit | 250.34M | 232.26M | 142.94M | 120.12M | -102.02M |
| Ebitda | 259.84M | 232.94M | 159.85M | 120.42M | -93.91M |
| Depreciation and amortization | 9.50M | 0.68M | 16.91M | 0.30M | 8.11M |
| Non operating income net other | 9.68M | -0.45M | -4.60M | -24.58M | -5.75M |
| Operating income | 250.34M | 232.26M | 142.94M | 120.12M | -238.89M |
| Other operating expenses | 160.26M | 181.54M | 231.20M | 311.37M | 448.66M |
| Interest expense | 7.60M | 31.15M | 29.48M | 36.60M | 34.73M |
| Tax provision | 77.36M | -327.79M | 2.69M | - | - |
| Interest income | 9.50M | 0.73M | 1.50M | 2.86M | 2.99M |
| Net interest income | 1.90M | -30.42M | -27.97M | -33.74M | -34.73M |
| Extraordinary items | - | - | - | -37.44M | -88.22M |
| Non recurring | - | - | 15.38M | 3.62M | 167.69M |
| Income tax expense | 77.36M | -327.79M | 2.69M | 74.26M | -5.75M |
| Total revenue | 410.60M | 413.75M | 389.52M | 428.41M | 346.64M |
| Total operating expenses | 160.26M | 181.54M | 228.06M | 287.49M | 415.90M |
| Cost of revenue | 0.00M | 0.00M | 3.14M | 23.88M | 32.75M |
| Total other income expense net | 2.08M | -31.60M | -34.08M | -61.18M | -145.62M |
| Discontinued operations | - | - | - | -37.44M | -88.22M |
| Net income from continuing ops | 175.06M | 528.45M | 106.18M | 58.94M | -282.37M |
| Net income applicable to common shares | 175.06M | 528.45M | 106.18M | 21.50M | -282.37M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 471.07M | 1100.52M | 1126.93M | 559.24M | 402.75M |
| Intangible assets | 3.68M | - | - | - | - |
| Other current assets | 12.01M | 7.71M | 11.05M | 10.92M | 11.94M |
| Total liab | 817.37M | 448.14M | 521.02M | 496.60M | 496.00M |
| Total stockholder equity | -346.30M | 652.38M | 605.91M | 62.64M | -93.25M |
| Deferred long term liab | - | - | - | 12.09M | 24.26M |
| Other current liab | 64.34M | 21.98M | 1.32M | 0.54M | 33.42M |
| Common stock | 0.16M | 0.15M | 0.16M | 0.16M | 0.16M |
| Capital stock | 0.16M | 0.15M | 0.16M | 0.16M | 0.16M |
| Retained earnings | -1698.62M | -696.38M | -937.61M | -1466.06M | -1572.23M |
| Other liab | - | 9.77M | 3.50M | 13.31M | 24.99M |
| Good will | - | - | - | 0.79M | 0.79M |
| Other assets | 0.00M | 299.58M | 358.78M | 54.47M | 64.94M |
| Cash | 92.15M | 656.20M | 620.13M | 362.56M | 177.02M |
| Total current liabilities | 276.10M | 25.52M | 161.70M | 32.71M | 40.93M |
| Current deferred revenue | 1.24M | - | 39.46M | 28.38M | 0.88M |
| Net debt | 623.38M | -240.29M | -144.33M | 91.14M | 254.20M |
| Short term debt | 202.69M | 3.06M | 119.98M | 3.13M | 1.15M |
| Short long term debt | 199.56M | - | 116.86M | - | - |
| Short long term debt total | 715.54M | 415.92M | 475.80M | 453.70M | 431.22M |
| Other stockholder equity | 1355.19M | 1348.60M | 1543.36M | 1528.54M | 1478.82M |
| Property plant equipment | - | 6.29M | 22.93M | 8.93M | 12.43M |
| Total current assets | 233.29M | 780.63M | 745.23M | 495.84M | 306.85M |
| Long term investments | - | 14.59M | 24.00M | 36.47M | 63.96M |
| Net tangible assets | - | 668.98M | 605.91M | 82.96M | -71.95M |
| Net receivables | 129.12M | 115.46M | 114.04M | 122.35M | 117.25M |
| Long term debt | 498.31M | 396.25M | 337.33M | 430.26M | 407.99M |
| Inventory | 0.00M | 1.25M | - | 0.00M | 0.65M |
| Accounts payable | 7.83M | 0.48M | 0.94M | 0.66M | 5.49M |
| Accumulated other comprehensive income | -3.03M | - | - | -11.80M | -10.08M |
| Common stock total equity | - | 0.15M | 0.16M | 0.16M | 0.16M |
| Retained earnings total equity | - | -696.38M | -937.61M | -1466.06M | -1572.23M |
| Non currrent assets other | 3.61M | 15.92M | 25.48M | 37.11M | 64.94M |
| Non current assets total | 237.78M | 319.89M | 381.70M | 63.40M | 95.90M |
| Capital lease obligations | 17.67M | 19.66M | 21.61M | 23.45M | 23.23M |
| Long term debt total | - | 396.25M | 337.33M | 430.26M | 407.99M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.14M | -0.27M | -1.84M | -11.14M | 95.92M |
| Change to liabilities | -7.93M | 10.08M | -7.55M | -33.18M | 8.96M |
| Total cashflows from investing activities | -0.14M | -0.27M | -1.84M | -11.14M | 88.87M |
| Net borrowings | -120.70M | -120.70M | -120.70M | 16.25M | -1.82M |
| Total cash from financing activities | -237.55M | -4.55M | 18.55M | -1.19M | 30.07M |
| Change to operating activities | 2.94M | 12.66M | 2.72M | 0.72M | -1.57M |
| Net income | 175.06M | 528.45M | 106.18M | 21.50M | -282.37M |
| Change in cash | 36.07M | 257.08M | 185.54M | -1.60M | 48.06M |
| Begin period cash flow | 621.86M | 364.78M | 179.24M | 180.85M | 132.79M |
| End period cash flow | 657.94M | 621.86M | 364.78M | 179.24M | 180.85M |
| Total cash from operating activities | 273.76M | 261.89M | 168.84M | 10.72M | -70.88M |
| Depreciation | 1.42M | 1.52M | 3.56M | 5.58M | 14.22M |
| Other cashflows from investing activities | - | - | - | -3.96M | 1.56M |
| Dividends paid | 111.16M | - | - | - | - |
| Change to inventory | 0.00M | 0.00M | 0.65M | 0.72M | -0.81M |
| Change to account receivables | 7.99M | 7.71M | 4.09M | -68.89M | 1.21M |
| Sale purchase of stock | -126.39M | -24.13M | 18.55M | 13.60M | 32.06M |
| Other cashflows from financing activities | 111.16M | 19.58M | 18.55M | 155.22M | 31.90M |
| Change to netincome | 91.49M | -321.69M | 19.47M | 90.00M | 104.43M |
| Capital expenditures | 0.14M | 0.27M | 1.84M | 7.19M | 8.62M |
| Change receivables | 7.99M | 7.71M | 4.09M | -68.89M | 1.21M |
| Cash flows other operating | 3.87M | 11.88M | 20.17M | -23.87M | 66.03M |
| Cash and cash equivalents changes | 36.07M | 257.08M | 185.54M | -1.60M | 48.06M |
| Change in working capital | 2.82M | 17.73M | -0.94M | -99.99M | 7.62M |
| Stock based compensation | 27.05M | 22.28M | 31.18M | 31.28M | 43.98M |
| Other non cash items | 1.67M | 25.21M | 22.26M | 16.42M | -13.44M |
| Free cash flow | 273.63M | 261.63M | 166.99M | 3.54M | -79.50M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals Inc |
-0.12 3.31% |
3.50 | - | 12.33 | 2.79 | 2.59 | 4.19 | -2.01 |
| MKKGY Merck KGaA ADR |
-0.01 0.03% |
33.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
0.04 0.02% |
169.25 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.90 4.50% |
20.91 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
4.03 10.61% |
42.00 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Ms. Julie H. McHugh | Exec. Chairman | 1964 |
| Mr. Thomas A. McCourt | CEO & Director | 1957 |
| Mr. Sravan Kumar Emany | Sr. VP, Principal Financial Officer & CFO | 1978 |
| Mr. Jason Rickard | Sr. VP & COO | 1971 |
| Mr. John Minardo | Sr. VP, Chief Legal Officer & Sec. | 1976 |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Sr. VP and Head of Research & Drug Devel. | 1959 |
| Mr. Ronald Silver | Corp. Controller & Principal Accounting Officer | 1982 |
| Mr. Marcel Moulaison | VP of Technical Operations | NA |
| Ms. Beth Calitri | Head of Corp. Communications & Media Relations | NA |
| Mr. Mike Nanfito | VP of Sales & Sales Excellence | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...